Intended for U.S. healthcare professionals only. For corporate information, please visit Mallinckrodt.com X
  • ULTRATAG™ RBC

    (kit for the preparation of technetium Tc 99m-labeled red blood cells)

    Ultratag RBC imaging agent uses a sterile, nonpyrogenic, diagnostic kit for the in vitro preparation of technetium Tc 99m-labeled red blood cells.

    It is approved for:

    • Blood pool imaging
    • Detection of sites of gastrointestinal bleeding
    • Cardiac first pass 
     

    Full US prescribing information

    Assembly of Ultratag RBC syringe components (7/17/2015)

    Ultratag Image

    Efficient
    The only FDA-approved in vitro red blood cell Tc 99m labeling agent with typical tagging efficiency of ≥95%.1

    Consistent
    Consistently high labeling yields, even in the presence of certain medications.1,2

    Confident
    Excellent target-to-background ratio1 from in vitro labeling helps in obtaining quality images.3,4

  • INDICATIONS AND USAGE

    Ultratag RBC Kit for the preparation of Technetium Tc 99m–Labeled Red Blood Cells are used for blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding.

    IMPORTANT RISK INFORMATION
     
    WARNINGS AND PRECAUTIONS

    • It is essential that the user follow the directions carefully and adhere to strict aseptic procedures during preparation.
    • The contents of the kit are intended only for use in the preparation of technetium Tc 99m-labeled red blood cells and are NOT to be administered directly to the patient.
    • The contents of this kit are not radioactive. After sodium pertechnetate Tc 99m is added, however, adequate shielding of the final preparation must be maintained.
    • Technetium Tc 99m-labeled red blood cells must be handled with care to ensure minimum radiation exposure to the patient, consistent with proper patient management, and to ensure minimum radiation exposure to occupational workers.
    • The labeled red blood cells must be reinjected only into the patient from whom the blood was drawn.
    • Nuclear medicine procedures involving withdrawal and reinjection of blood have the potential for transmission of blood borne pathogens. Procedures should be implemented to avoid administration errors and viral contamination of personnel during blood product labeling.
    • The labeled red blood cells be administered within 30 minutes of preparation or as soon as possible thereafter.
    • Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides.

    USE IN SPECIFIC POPULATIONS

    • Breastfeeding: should be discontinued because Technetium Tc 99m is excreted in human milk.
    • Safety and effectiveness in pediatric patients have not been established.

     

    1. Ultratag™ RBC package insert. St. Louis, MO: Mallinckrodt, Inc.; 2005.
    2. Spicer JA, Hladik WB III, Mulberry WE. The effects of selected antineoplastic agents on the labeling of erythrocytes with technetium-99m using the Ultratag RBC kit. J Nucl Med Technol. 1999;27:132-135.
    3. Patrick ST, Glowniak JV, Turner FE. Comparison of in vitro RBC labeling with the Ultratag™ RBC kit versus in vivo labeling. J Nucl Med. February 1991;32:242-244.
    4. Taylor A, Schuster DM, Alazraki N. A Clinician's Guide to Nuclear Medicine. 2nd ed. Society of Nuclear Medicine, Inc. 2006;12.